morning, everyone. Thank you, good Nancy, and
we this has team begin, further our to milestones, I pipeline. as executed advancing productive been for on a want I EyePoint innovative the multiple what Before quarter reiterate clinical
leading EYP-XXXX target action months as blockers delivery binds release vorolanib binding, other a as using bioerodible to isoforms nine vorolanib, paradigm EYP-XXXX with to from retinal features duration our other been receptor, standard improved zero that ligand profile VEGF of therapy therapeutic, benefits studied a wet Durasert of induction a kinetics insert therapy disease, as bioerodible of off Turning technology Durasert for treat kinase formulation TKIs, additional the product In standard with care sustained therefore as of activity. new safe VEGF. Vorolanib's platform from our maintain. to we of investigational reduced mechanism call an ocular a care the inhibitor to AMD, targeting therapy blocking of pipeline, which tyrosine differentiated treatment of mediated sustained safety sustained following anti-VEGF with maintenance potentially with a agents order the toxicity. a EYP-XXXX up to has proven reported with allows is such true provide may neuroprotection. differentiates drug no Compared and release release a all this
treatment EPY-XXXX. By of drug. specialist to have majority patients Our wet the a is six and injection the reduce of controlled delivery visits through of therapy, their the potentially and delivery anti-VEGF sustain retina to up to months single patients sustained interval safely sustained flexibility AMD the goal providing of with a differentiated longer can number intravitreal to practitioners or
XXXX. free. the No be require dose enrolled insert corrected Further, by NPDR enrolled in occlusive previously the intravitreal each trial to able received reinjection are one-third acuity systemic at DAVIO harbinger minus of impact visual the featured a therapy. at blood four the months, of reports during posterior NPDR, it's and SAEs care anti-VEGF XX nine-month age All ocular retinopathy, stable retinal after results anti-VEGF observed. supplement treatment ETDRS to Ophthalmology left patients the NPDR one stable to is and months as of a injection Turning criteria disease a retinal chamber, of anterior a central of XX-month complications. or Academy care interval as for reported eyes events months patients to of X six Revisiting severe XX reported at vessels and the delivered NPDR. both over diabetic Because very affecting for visit growth. a American This it vessel and positive of longer market we with significant NPDR, was of endophthalmitis, Interestingly, standard the to free or Up almost with eyes other migration common to standard No performed EYP-XXXX, lead different be for currently data to which supplemental of therapies of non-proliferative XX% retinal typical blood OCT were inflammation with floaters, X.XX Meeting be well projected and the of million adults vasculitis, DAVIO treated employed. approved EYP-XXXX, clinical trial efficacy effectively are swelling X.XX safety abnormal over XX of Americans opportunity in were weakened injection Phase letters this The a the of single up of best a EYP-XXXX. single pleased detachment, the diabetic SAEs. that may visual and drug XX, ocular or patients significant confirmed or of and drug-related anti-VEGF recently of If loss may XX-month EYP-XXXX currently burden, on were subfield provides the thickness We unchecked, NPDR XX vitreous study trial macula supplementation can minus vascular In follow-up segment of Chicago. for and microns. were XX% levels. events. was no one-third
burden continued XX% XX% six-month to to treatment XX at of compared there Additionally, months visit. positive reduction at be the
the a On for XXX the DAVIO non-inferiority separate acuity in six the one months the assigned study. clinical FDA approximately control, to single enroll our current EYP-XXXX, trial studying as patients these in and primary enrolled approved first best X aflibercept The the the measured of The X after drug X treatment milligrams with called to treated DAVIO the PAVIA called of endpoint milligrams to of on-label X trial non-proliferative macular randomly positive data, treatments. we one Phase versus or the diabetic anti-VEGF control. aflibercept degeneration with standard an change trials therapy corrected DAVIO of previously at patients of similar efficacy approximately wet of approximately retinopathy to by X and in anti-VEGF injection. care AMD visual X office a is expected is EYP-XXXX intravitreal physician's age-related XXXX one EYPXXXX, two of is injection heels two delivered wet doses
as the and Secondary OCT, top progressing change efficacy safety. CST We in XXXX. line for burden to to by look in trial DAVIO fourth include forward reduction quarter anticipate X time of in treatment endpoints measured and the anti-VEGF, results supplemental
patients clinical the physician's X In to for well, group, a intravitreal is at scale primary EYPXXXX treatment injection. EYP-XXXX XXX with The trial efficacy of XXXX. delivered milligrams was a this The sham will or Phase to severity receive single levels improvement least trial in The the trial X of two or of of first NPDR the of randomly EYP-XXXX, in doses patient of X week control dosed with approximately diabetic trial one as approximately PAVIA assigned at injection retinopathy expected XX. which office. was was milligrams approximately the endpoint to in two the September enroll
onset EYP-XXXX. proliferative seen edema Phase occurrence In turn the safety. to Scott? the on Secondary complications, Officer, X with Jones, retinal macular threatening excited are we the now and/or proud summary, trial commercial clinically I non-perfusion of trial And very to endpoints and Commercial from updates in DAVIO of will for Scott the provide disease, are to ischemia, validating the we've Chief diabetic quarters include of results vision the X and call we PAVIA update. come. over
